COMPASS Pathways plc
CMPS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001816590
No open-market purchases or sales by COMPASS Pathways plc insiders were filed in the last 90 days; 224 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by COMPASS Pathways plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for COMPASS Pathways plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Nath Kabir | Chief Executive Officer | 361,028 | Aug 5, 2026 | 4 |
| Jonas Jeffrey M | Director | – | May 29, 2026 | 2 |
| Santini Gino | Director | – | May 29, 2026 | 1 |
| Riley Wayne Joseph | Director | – | May 29, 2026 | 1 |
| Norton David Y | Director | 20,356 | May 29, 2026 | 1 |
| Gover Justin D. | Director | – | May 29, 2026 | 1 |
| Karydas Daphne | Director | – | May 29, 2026 | 1 |
| Tregoning Kathleen | Director | – | May 29, 2026 | 1 |
| McQuade Robert | Director | – | May 29, 2026 | 1 |
| Loxam Teri | Chief Financial Officer | 152,002 | Mar 27, 2026 | 3 |
| Goodwin Guy | Chief Medical Officer | 8,000 | Mar 27, 2026 | 1 |
| McGoldrick Linda | Director | – | Jun 13, 2025 | 0 |
| Jenkins Annalisa | Director | 19,480 | Jun 13, 2025 | 0 |
| Lonngren Thomas | Director | – | Jun 13, 2025 | 0 |
| Goldsmith George Jay | 10% Owner | 3,152,848Indirect | Oct 25, 2024 | 0 |
| Malievskaia Ekaterina | 10% Owner | 3,155,122Indirect | Oct 25, 2024 | 0 |
| ATAI Life Sciences AG | 10% Owner | 6,905,774Indirect | Sep 27, 2024 | 0 |
| ATAI Life Sciences N.V. | 10% Owner | 6,905,774Indirect | Sep 27, 2024 | 0 |
| Owens Matthew A | General Counsel & CLO | 43,340 | Feb 5, 2024 | 0 |
| Hughes Mary-Rose | Interim CFO | – | Feb 5, 2024 | 0 |
| Falvey Michael | Chief Financial Officer | 22,500 | Feb 3, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Malievskaia EkaterinaChief Innovation Officer | SSale | −6.37K | $12.48 | −$79.5K | −0.1%4.28M after | Duplicate filing |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Goldsmith George JayChief Executive Officer | SSale | −6.37K | $12.48 | −$79.5K | −0.1%4.28M after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Goldsmith George JayChief Executive Officer | SSale | −6.37K | $12.48 | −$79.5K | −0.1%4.27M after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Norton David YDirector | SSale | −3.38K | $12.48 | −$42.2K | −14.3%20.4K after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Jenkins AnnalisaDirector | SSale | −3.38K | $12.48 | −$42.2K | −14.3%20.4K after |